AstraZeneca completes commercialisation agreement with Aspen for anaesthetics portfolio

The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest). As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment (to be recognised in the third quarter of 2016), along with all future milestone and royalty payments, will be reported as Externalisation Revenue in the Company’s financial statements.

* With the exception of Ukraine and Zimbabwe, which are subject to separate closing

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com 

  *******

CONTACTS

 _________________________________________________________________________________